Product Reports Resources Pricing Login Book a demo

Revance Therapeutics

Biotech & Life Sciences · Nashville, United States · Founded 2002 · IPO 2014

Revance Therapeutics, Inc. is a biotechnology company that specializes in innovative aesthetic and therapeutic solutions. The company operates primarily in the aesthetics market, focusing on products that enhance physical appearance and improve patient outcomes. Revance serves a variety of clients, including healthcare professionals, aesthetic practitioners, and patients seeking minimally invasive cosmetic procedures. Revance's product portfolio includes neuromodulators and dermal fillers, which are among the most popular minimally invasive cosmetic treatments. Neuromodulators, such as botulinum toxin type A, are used to reduce wrinkles and treat muscle movement disorders. Dermal fillers are used to restore volume and smooth out facial lines. The company is also exploring therapeutic applications for its products in treating muscle movement and pain disorders, aiming to significantly improve patient experiences. In addition to its core product offerings, Revance has recently expanded into the financial technology (fintech) sector with the acquisition of HintMD. This platform is designed to streamline payment processes for aesthetic practices, enhancing the overall experience for both practitioners and patients. By integrating fintech solutions, Revance aims to provide a comprehensive suite of services that support the business operations of aesthetic practices. Revance's business model is built on the development, marketing, and distribution of its innovative products. The company generates revenue through the sale of its neuromodulators and dermal fillers, as well as through its fintech platform, which offers subscription-based services to aesthetic practices. By focusing on differentiated products and improved outcomes, Revance aims to establish itself as a leader in the premium aesthetics market. Keywords: biotechnology, aesthetics, neuromodulators, dermal fillers, fintech, HintMD, muscle movement disorders, pain disorders, healthcare professionals, innovative solutions.

Valuation $643M
Revenue $234M
Total funding $100–500M
Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Investors

9 investors on Revance Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage
EW Healthcare Partners
Technology Partners
Essex Woodlands Health Ventures
Vivo Capital
Series B+ 5 investors entered at this stage
Palo Alto Investors
Shepherd Ventures
Bausch Health Companies
NovaQuest Capital Management
Athyrium Capital Management

Global footprint

Where Revance Therapeutics has talent and traffic

Workforce by country
11 countries with
team presence
🇺🇸 United States96.5%
🇬🇧 United Kingdom0.9%
🇩🇪 Germany0.9%
🇨🇦 Canada0.4%
🇮🇪 Ireland0.2%
Top 5 of 11 shown
Web traffic by country
23K monthly visits
across markets
🇺🇸 United States77%
🇵🇭 Philippines7%
🇨🇦 Canada4.3%
🇮🇳 India3%
🇫🇷 France2.6%
Top 5 markets shown

Talent graph

The shape of Revance Therapeutics's talent

Dealroom maps Revance Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

27 standout operatorsDealroom-flagged across the org
5 AI specialistspinpointed by name
777 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Revance Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$40M patent portfolio · 27 active families

Estimated portfolio value
$40M
6.3% of market cap · 143.2× smaller than top peer Ablynx ($5.8B)
27 active patent families
Where Revance Therapeutics innovates Botulinum toxinBotulinum toxin aDiseaseDrugMedicine

Where Revance Therapeutics concentrates vs peers

Each axis is a top-10 topic across Revance Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Revance Therapeutics

An AI-synthesized read of the highest-engagement posts about Revance Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Revance Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles